This is a routine board expansion with a regulatory-savvy director. The key catalyst to watch is the company's ability to secure funding for the Phase 3b ENDURANCE trial, which is explicitly contingent on 'acquisition of necessary funding.' Monitor for capital raise announcements in coming months.
Price Chart
Executive Summary
Brainstorm Cell Therapeutics appointed former FDA Associate Commissioner Peter Pitts to its Board of Directors, expanding the board from seven to eight members. The appointment comes as the company prepares to initiate its Phase 3b ENDURANCE ALS trial under a recently executed Special Protocol Assessment (SPA) from the FDA, conditional on obtaining necessary funding. This is a routine director appointment with no financial impact disclosed, though the regulatory expertise adds potential strategic value.
Key Facts
- Peter Pitts appointed to board effective May 25, 2026, expanding board from 7 to 8 directors
- Pitts is former FDA Associate Commissioner and President of Center for Medicine in the Public Interest
- Received option for 150,000 common shares; half vested immediately, half at 6-month anniversary
- Company preparing to initiate Phase 3b ENDURANCE ALS trial under SPA, subject to funding
- Standard indemnification agreement to be entered into with Pitts
Financial Impact
150,000 share option grant to new director, standard indemnification agreement — no material financial impact disclosed
Risk Factors
- Phase 3b trial initiation requires additional funding — no financing commitments disclosed
- Stock trades on OTCQB, limited liquidity
- Historical analyst consensus is predominantly bearish (0% buy rating)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-067474 |
| Document: tm2615772d1_8k.htm | 0001104659-26-067474 |
| Document: tm2615772d1_ex99-1.htm | 0001104659-26-067474 |
| Document: 0001104659-26-067474-index-headers.html | 0001104659-26-067474 |
| Document: 0001104659-26-067474-index.html | 0001104659-26-067474 |
| Document: 0001104659-26-067474.txt | 0001104659-26-067474 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 3, 2026 20w ago | EFFECT | $0.7700 $0.8300 | ▼ −7.79% | ▼ −11.61% | $0.7527 (+2.25%) |
May 28, 2026 21w ago | 8-K | $0.7500 $0.7500 | · 0.00% | ▲ +2.52% | $0.7527 (+0.36%) |
May 15, 2026 23w ago | 8-K | $0.6900 $0.6300 | ▲ +8.70% | ▲ +10.31% | $0.7527 (−9.09%) |
Mar 31, 2026 29w ago | 8-K | $0.9500 $0.9100 | ▼ −4.21% | ▼ −7.98% | $0.7527 (−20.77%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers